StockData
Aurinia Pharmaceuticals Inc. logo

Aurinia Pharmaceuticals Inc. (AUPH) stock

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3062% below fair value
$15.73−0.48 (-2.96%)

Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –

Earnings

Aurinia Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$83.70M
+13.9% on a year earlier
EPS, Q3 FY2026
$0.23
$0.23 a year earlier
Latest guidance
Issued
Oct 30, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Aurinia Pharmaceuticals's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Feb 25, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Oct 30, 2026before the open$83.70M+13.9%$0.23Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026before the open$83.22M+18.9%$0.28Release
Q1 FY2026ended Mar 31, 2026May 7, 2026before the open$77.70M+24.3%$0.25Release
Q4 FY2025ended Dec 31, 2025Feb 26, 2026before the open$77.10M+28.7%$1.53Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025before the open$73.47M+8.4%$0.23Release
Q2 FY2025ended Jun 30, 2025Jul 31, 2025before the open$70.00M+22.4%$0.16Release
Q1 FY2025ended Mar 31, 2025May 12, 2025before the open$62.50M–$0.16Release
Q4 FY2024ended Dec 31, 2024Feb 27, 2025before the open$59.90M+32.8%$0.01Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024before the open$67.80M+24.4%$0.10Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024before the open$57.20M+37.8%$0.01Release
Q4 FY2023ended Dec 31, 2023Feb 15, 2024before the open$45.10M+58.8%-$0.19Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Aurinia Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
total revenueFY2026$325.00M – $330.00M–NewOct 30, 2026
total revenueFY2026$315.00M – $325.00M$315.00M – $325.00MReaffirmedAug 6, 2026
total revenue growthFY2026+11% – +15%–NewMay 7, 2026
net product salesFY2026$310.00M – $315.00M–NewOct 30, 2026
net product salesFY2026$305.00M – $315.00M$305.00M – $315.00MReaffirmedAug 6, 2026
net product sales growthFY2026+12% – +16%–NewMay 7, 2026

Guidance vs results

The last range Aurinia Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$275.00M – $280.00M$283.07MΣ4QAbove range

Guidance history

Every forecast Aurinia Pharmaceuticals put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 30, 2026net product salesFY2026$310.00M – $315.00MNew
Oct 30, 2026total revenueFY2026$325.00M – $330.00MNew
Aug 6, 2026net product salesFY2026$305.00M – $315.00MReaffirmed
Aug 6, 2026total revenueFY2026$315.00M – $325.00MReaffirmed
May 7, 2026net product sales growthFY2026+12% – +16%New
May 7, 2026net product salesFY2026$305.00M – $315.00MReaffirmed
May 7, 2026total revenue growthFY2026+11% – +15%New
May 7, 2026total revenueFY2026$315.00M – $325.00MReaffirmed
Feb 26, 2026net product salesFY2026$305.00M – $315.00MNew
Feb 26, 2026total revenueFY2026$315.00M – $325.00MNew
Nov 4, 2025net product salesFY2025$265.00M – $270.00MNew
Nov 4, 2025total revenueFY2025$275.00M – $280.00MNew
Jul 31, 2025net product salesFY2025$250.00M – $260.00MRaised
Jul 31, 2025total revenueFY2025$260.00M – $270.00MRaised
May 12, 2025net product salesFY2025$240.00M – $250.00MReaffirmed
May 12, 2025total revenueFY2025$250.00M – $260.00MReaffirmed
Feb 27, 2025net product salesFY2025$240.00M – $250.00MNew
Feb 27, 2025total revenueFY2025$250.00M – $260.00MNew
Nov 7, 2024one-time restructuring chargeQ4 FY2024$15.00M – $19.00MNew
Nov 7, 2024net product revenue guidance rangeFY2024$210.00M – $220.00MReaffirmed

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Aurinia Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K

  1. Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended
    Results
  2. Aurinia Settles Patent Litigation with Teva
    News
  3. Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
    Results
  4. Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
    Results
  5. Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
    Update
  6. Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
    Results
  7. Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
    Results
  8. ® Third Quarter 2025 Update November 4, 2025
    Results
  9. Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
    Results
  10. Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
    News
  11. June 30, 2025 Aritinercept (AUR200) A Dual BAFF/APRIL Inhibitor for the Potential Treatment of Autoimmune Diseases Results from a Phase 1 Study
    News
  12. Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
    Results
  13. Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
    Results
  14. Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results,
    Results
  15. Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
    Results

See a number that looks wrong?